Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

U.S. Arm Of Indian Glenmark Settles Patent Suits With  Teva

This article was originally published in PharmAsia News

Executive Summary

The U.S. subsidiary of India's Glenmark Pharmaceuticals and Israel's Teva have settled a patent dispute in a U.S. court involving Teva's Coreg (carvedilol) for treating congestive heart failure. Glenmark Generics had used a process patent to prepare the compound, sparking a suit by Teva, and Glenmark responded with a challenge of its own against two Teva patents for Coreg. The two companies settled their disputes out of court and the judge in the case accepted. Two other Indian drug makers, Ranbaxy and Dr. Reddy's, earlier settled out of court with Teva over the same drug. (Click here for more
Advertisement

Related Content

Armed With Three New Compounds, Glenmark Readies for More Out-licensing Opportunities
Advertisement
UsernamePublicRestriction

Register

SC071433

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel